Randomized Clinical Trial of Long-Acting Somatostatin for Autosomal Dominant Polycystic Kidney and Liver Disease

There are no proven, effective therapies for polycystic kidney disease (PKD) or polycystic liver disease (PLD). We enrolled 42 patients with severe PLD resulting from autosomal dominant PKD (ADPKD) or autosomal dominant PLD (ADPLD) in a randomized, double-blind, placebo-controlled trial of octreotid...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the American Society of Nephrology 2010-06, Vol.21 (6), p.1052-1061
Hauptverfasser:	HOGAN, Marie C, MASYUK, Tetyana V, ROSSETTI, Sandro, HARRIS, Peter C, LARUSSO, Nicholas F, TORRES, Vicente E, PAGE, Linda J, KUBLY, Vickie J, BERGSTRALH, Eric J, XUJIAN LI, KIM, Bohyun, KING, Bernard F, GLOCKNER, James, HOLMES, David R
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Biological and medical sciences Clinical Research Double-Blind Method Female Glomerular Filtration Rate - drug effects Humans Kidney - drug effects Kidney - pathology Kidney - physiopathology Kidneys Liver - drug effects Liver - enzymology Liver - pathology Liver Diseases - drug therapy Liver Diseases - physiopathology Male Malformations of the urinary system Medical sciences Middle Aged Nephrology. Urinary tract diseases Octreotide - adverse effects Octreotide - pharmacology Octreotide - therapeutic use Organ Size - drug effects Polycystic Kidney, Autosomal Dominant - drug therapy Polycystic Kidney, Autosomal Dominant - physiopathology Somatostatin - analogs & derivatives Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!